{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+controlled&page=10", "query": { "intervention": "Placebo controlled", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 33013, "total_pages": 3302, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+controlled&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+controlled&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T08:24:16.940Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04497844", "title": "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Niraparib+ Abiraterone acetate fixed dose combination (FDC)", "type": "COMBINATION_PRODUCT" }, { "name": "Abiraterone acetate (AA)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo FDC", "type": "DRUG" }, { "name": "Placebo AA", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 696, "start_date": "2020-09-23", "completion_date": "2027-11-01", "has_results": true, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 53, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04497844" }, { "nct_id": "NCT04707664", "title": "Sargramostim Use in COVID-19 to Recover Patient Health", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19", "SARS-CoV Infection" ], "interventions": [ { "name": "Sargramostim", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Partner Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2021-04-27", "completion_date": "2022-01-31", "has_results": true, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Canoga Park", "state": "California" }, { "city": "Colton", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04707664" }, { "nct_id": "NCT01321463", "title": "Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "PH-797804", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 377, "start_date": "2011-05", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2013-07-11", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 22, "location_summary": "Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01321463" }, { "nct_id": "NCT01898806", "title": "Intralesional Steroids in the Treatment of Alopecia Areata", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "Intralesional Triamcinolone 2.5 mg/ml", "type": "DRUG" }, { "name": "Intralesional Triamcinolone 5 mg/ml", "type": "DRUG" }, { "name": "Intralesional Triamcinolone 10 mg/ml", "type": "DRUG" }, { "name": "Intralesional Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2011-09", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • New York, New York", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01898806" }, { "nct_id": "NCT02277704", "title": "Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 245, "start_date": "2014-10", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 23, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Imperial", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277704" }, { "nct_id": "NCT02317549", "title": "Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Septic Shock" ], "interventions": [ { "name": "LB1148", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leading BioSciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 8, "start_date": "2015-04", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2020-06-01", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 26, "location_summary": "Mobile, Alabama • Fresno, California • Long Beach, California + 23 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02317549" }, { "nct_id": "NCT02450838", "title": "Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dengue" ], "interventions": [ { "name": "V180", "type": "BIOLOGICAL" }, { "name": "Alhydrogel™", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 20, "start_date": "2015-04", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2016-04-04", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Burlington, Vermont", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Burlington", "state": "Vermont" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT02450838" }, { "nct_id": "NCT00358358", "title": "Chronic Obstructive Pulmonary Disease Endpoints Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Propionate/Salmeterol 500/50mcg combination", "type": "DRUG" }, { "name": "Fluticasone Propionate 500mcg", "type": "DRUG" }, { "name": "Salmeterol 50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 163, "start_date": "2006-03", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 4, "location_summary": "Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more", "locations": [ { "city": "Absecon", "state": "New Jersey" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358358" }, { "nct_id": "NCT01907100", "title": "Nintedanib (BIBF 1120) in Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2013-09-19", "completion_date": "2018-08-31", "has_results": true, "last_update_posted_date": "2019-03-18", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907100" }, { "nct_id": "NCT02311907", "title": "Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapeutic Agent Toxicity", "Neuropathy", "Neurotoxicity Syndrome", "Pain", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Glutathione", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2009-12", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-11-15T08:24:16.940Z", "location_count": 390, "location_summary": "Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fairfield", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311907" } ] }